Table 2 Patient characteristics during ICU stay according to disease groups and 28-day mortality
SARS-CoV-2 pneumonia | Influenza pneumonia | No viral infection | ||||
|---|---|---|---|---|---|---|
Alive (n = 402) | Dead (n = 166) | Alive (n = 350) | Dead (n = 132) | Alive (n = 344) | Dead (n = 182) | |
Antiviral treatment | 226/401 (56.4) | 96/165 (58.2) | 319/349 (91.4) | 118/132 (89.4) | 19/343 (5.5) | 5/180 (2.8) |
Oseltamivir | 30/399 (7.5) | 14/164 (8.5) | 314/344 (91.3) | 116/131 (88.5) | 18/342 (5.3) | 4/179 (2.2) |
Remdesivir | 21/399 (5.3) | 6/164 (3.7) | 0/344 (0.0) | 0/131 (0.0) | 0/342 (0.0) | 0/179 (0.0) |
Lopinavir-Ritonavir | 96/399 (24.1) | 51/164 (31.1) | 0/344 (0.0) | 0/131 (0.0) | 0/342 (0.0) | 0/179 (0.0) |
Lopinavir-Ritonavir + interferon | 12/399 (3.0) | 9/164 (5.5) | 0/344 (0.0) | 0/131 (0.0) | 0/342 (0.0) | 0/179 (0.0) |
Hydroxychloroquine | 134/399 (33.6) | 39/164 (23.8) | 0/344 (0.0) | 1/131 (0.8) | 0/342 (0.0) | 0/179 (0.0) |
Corticosteroids | 131/380 (34.5) | 71/162 (43.8) | 124/345 (35.9) | 58/130 (44.6) | 97/343 (28.3) | 64/182 (35.2) |
Hydrocortisone | 27/377 (7.2) | 32/160 (20.0) | 64/343 (18.7) | 43/130 (33.1) | 39/340 (11.5) | 41/180 (22.8) |
Dexamethasone | 32/377 (8.5) | 16/160 (10.0) | 1/343 (0.3) | 0/130 (0.0) | 6/340 (1.8) | 4/180 (2.2) |
Methylprednisolone | 70/377 (18.6) | 21/160 (13.1) | 58/343 (16.9) | 15/130 (11.5) | 51/340 (15.0) | 17/180 (9.4) |
Highest daily dose, mga | 100 (67–133) | 71 (50–133) | 75 (50–100) | 50 (50–100) | 63 (50–100) | 50 (50–75) |
Duration, daysb | 6 (4–9) | 6 (4–8) | 5 (3–9) | 6 (3–9) | 4 (2–7) | 4 (3–8) |
Antibiotic treatment | 363/378 (96.0) | 143/153 (93.5) | 309/330 (93.6) | 125/128 (97.7) | 268/323 (83.0) | 147/173 (85.0) |
Duration, days | 7 (5–9) | 7 (4–10) | 7 (5–11) | 7 (4–9) | 7 (4–9) | 6 (4–9) |
Prone positioning | 263/401 (65.6) | 120/166 (72.3) | 96/349 (27.5) | 55/132 (41.7) | 33/340 (9.7) | 30/182 (16.5) |
ECMO | 39/402 (9.7) | 22/165 (13.3) | 38/349 (10.9) | 22/131 (16.8) | 2/341 (0.6) | 3/182 (1.6) |